Cargando…

An Integrated Drosophila Model System Reveals Unique Properties for F14512, a Novel Polyamine-Containing Anticancer Drug That Targets Topoisomerase II

F14512 is a novel anti-tumor molecule based on an epipodophyllotoxin core coupled to a cancer-cell vectoring spermine moiety. This polyamine linkage is assumed to ensure the preferential uptake of F14512 by cancer cells, strong interaction with DNA and potent inhibition of topoisomerase II (Topo II)...

Descripción completa

Detalles Bibliográficos
Autores principales: Chelouah, Sonia, Monod-Wissler, Caroline, Bailly, Christian, Barret, Jean-Marc, Guilbaud, Nicolas, Vispé, Stéphane, Käs, Emmanuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3154508/
https://www.ncbi.nlm.nih.gov/pubmed/21853156
http://dx.doi.org/10.1371/journal.pone.0023597
_version_ 1782210026932273152
author Chelouah, Sonia
Monod-Wissler, Caroline
Bailly, Christian
Barret, Jean-Marc
Guilbaud, Nicolas
Vispé, Stéphane
Käs, Emmanuel
author_facet Chelouah, Sonia
Monod-Wissler, Caroline
Bailly, Christian
Barret, Jean-Marc
Guilbaud, Nicolas
Vispé, Stéphane
Käs, Emmanuel
author_sort Chelouah, Sonia
collection PubMed
description F14512 is a novel anti-tumor molecule based on an epipodophyllotoxin core coupled to a cancer-cell vectoring spermine moiety. This polyamine linkage is assumed to ensure the preferential uptake of F14512 by cancer cells, strong interaction with DNA and potent inhibition of topoisomerase II (Topo II). The antitumor activity of F14512 in human tumor models is significantly higher than that of other epipodophyllotoxins in spite of a lower induction of DNA breakage. Hence, the demonstrated superiority of F14512 over other Topo II poisons might not result solely from its preferential uptake by cancer cells, but could also be due to unique effects on Topo II interactions with DNA. To further dissect the mechanism of action of F14512, we used Drosophila melanogaster mutants whose genetic background leads to an easily scored phenotype that is sensitive to changes in Topo II activity and/or localization. F14512 has antiproliferative properties in Drosophila cells and stabilizes ternary Topo II/DNA cleavable complexes at unique sites located in moderately repeated sequences, suggesting that the drug specifically targets a select and limited subset of genomic sequences. Feeding F14512 to developing mutant Drosophila larvae led to the recovery of flies expressing a striking phenotype, "Eye wide shut," where one eye is replaced by a first thoracic segment. Other recovered F14512-induced gain- and loss-of-function phenotypes similarly correspond to precise genetic dysfunctions. These complex in vivo results obtained in a whole developing organism can be reconciled with known genetic anomalies and constitute a remarkable instance of specific alterations of gene expression by ingestion of a drug. "Drosophila-based anticancer pharmacology" hence reveals unique properties for F14512, demonstrating the usefulness of an assay system that provides a low-cost, rapid and effective complement to mammalian models and permits the elucidation of fundamental mechanisms of action of candidate drugs of therapeutic interest in humans.
format Online
Article
Text
id pubmed-3154508
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-31545082011-08-18 An Integrated Drosophila Model System Reveals Unique Properties for F14512, a Novel Polyamine-Containing Anticancer Drug That Targets Topoisomerase II Chelouah, Sonia Monod-Wissler, Caroline Bailly, Christian Barret, Jean-Marc Guilbaud, Nicolas Vispé, Stéphane Käs, Emmanuel PLoS One Research Article F14512 is a novel anti-tumor molecule based on an epipodophyllotoxin core coupled to a cancer-cell vectoring spermine moiety. This polyamine linkage is assumed to ensure the preferential uptake of F14512 by cancer cells, strong interaction with DNA and potent inhibition of topoisomerase II (Topo II). The antitumor activity of F14512 in human tumor models is significantly higher than that of other epipodophyllotoxins in spite of a lower induction of DNA breakage. Hence, the demonstrated superiority of F14512 over other Topo II poisons might not result solely from its preferential uptake by cancer cells, but could also be due to unique effects on Topo II interactions with DNA. To further dissect the mechanism of action of F14512, we used Drosophila melanogaster mutants whose genetic background leads to an easily scored phenotype that is sensitive to changes in Topo II activity and/or localization. F14512 has antiproliferative properties in Drosophila cells and stabilizes ternary Topo II/DNA cleavable complexes at unique sites located in moderately repeated sequences, suggesting that the drug specifically targets a select and limited subset of genomic sequences. Feeding F14512 to developing mutant Drosophila larvae led to the recovery of flies expressing a striking phenotype, "Eye wide shut," where one eye is replaced by a first thoracic segment. Other recovered F14512-induced gain- and loss-of-function phenotypes similarly correspond to precise genetic dysfunctions. These complex in vivo results obtained in a whole developing organism can be reconciled with known genetic anomalies and constitute a remarkable instance of specific alterations of gene expression by ingestion of a drug. "Drosophila-based anticancer pharmacology" hence reveals unique properties for F14512, demonstrating the usefulness of an assay system that provides a low-cost, rapid and effective complement to mammalian models and permits the elucidation of fundamental mechanisms of action of candidate drugs of therapeutic interest in humans. Public Library of Science 2011-08-10 /pmc/articles/PMC3154508/ /pubmed/21853156 http://dx.doi.org/10.1371/journal.pone.0023597 Text en Chelouah et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Chelouah, Sonia
Monod-Wissler, Caroline
Bailly, Christian
Barret, Jean-Marc
Guilbaud, Nicolas
Vispé, Stéphane
Käs, Emmanuel
An Integrated Drosophila Model System Reveals Unique Properties for F14512, a Novel Polyamine-Containing Anticancer Drug That Targets Topoisomerase II
title An Integrated Drosophila Model System Reveals Unique Properties for F14512, a Novel Polyamine-Containing Anticancer Drug That Targets Topoisomerase II
title_full An Integrated Drosophila Model System Reveals Unique Properties for F14512, a Novel Polyamine-Containing Anticancer Drug That Targets Topoisomerase II
title_fullStr An Integrated Drosophila Model System Reveals Unique Properties for F14512, a Novel Polyamine-Containing Anticancer Drug That Targets Topoisomerase II
title_full_unstemmed An Integrated Drosophila Model System Reveals Unique Properties for F14512, a Novel Polyamine-Containing Anticancer Drug That Targets Topoisomerase II
title_short An Integrated Drosophila Model System Reveals Unique Properties for F14512, a Novel Polyamine-Containing Anticancer Drug That Targets Topoisomerase II
title_sort integrated drosophila model system reveals unique properties for f14512, a novel polyamine-containing anticancer drug that targets topoisomerase ii
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3154508/
https://www.ncbi.nlm.nih.gov/pubmed/21853156
http://dx.doi.org/10.1371/journal.pone.0023597
work_keys_str_mv AT chelouahsonia anintegrateddrosophilamodelsystemrevealsuniquepropertiesforf14512anovelpolyaminecontaininganticancerdrugthattargetstopoisomeraseii
AT monodwisslercaroline anintegrateddrosophilamodelsystemrevealsuniquepropertiesforf14512anovelpolyaminecontaininganticancerdrugthattargetstopoisomeraseii
AT baillychristian anintegrateddrosophilamodelsystemrevealsuniquepropertiesforf14512anovelpolyaminecontaininganticancerdrugthattargetstopoisomeraseii
AT barretjeanmarc anintegrateddrosophilamodelsystemrevealsuniquepropertiesforf14512anovelpolyaminecontaininganticancerdrugthattargetstopoisomeraseii
AT guilbaudnicolas anintegrateddrosophilamodelsystemrevealsuniquepropertiesforf14512anovelpolyaminecontaininganticancerdrugthattargetstopoisomeraseii
AT vispestephane anintegrateddrosophilamodelsystemrevealsuniquepropertiesforf14512anovelpolyaminecontaininganticancerdrugthattargetstopoisomeraseii
AT kasemmanuel anintegrateddrosophilamodelsystemrevealsuniquepropertiesforf14512anovelpolyaminecontaininganticancerdrugthattargetstopoisomeraseii
AT chelouahsonia integrateddrosophilamodelsystemrevealsuniquepropertiesforf14512anovelpolyaminecontaininganticancerdrugthattargetstopoisomeraseii
AT monodwisslercaroline integrateddrosophilamodelsystemrevealsuniquepropertiesforf14512anovelpolyaminecontaininganticancerdrugthattargetstopoisomeraseii
AT baillychristian integrateddrosophilamodelsystemrevealsuniquepropertiesforf14512anovelpolyaminecontaininganticancerdrugthattargetstopoisomeraseii
AT barretjeanmarc integrateddrosophilamodelsystemrevealsuniquepropertiesforf14512anovelpolyaminecontaininganticancerdrugthattargetstopoisomeraseii
AT guilbaudnicolas integrateddrosophilamodelsystemrevealsuniquepropertiesforf14512anovelpolyaminecontaininganticancerdrugthattargetstopoisomeraseii
AT vispestephane integrateddrosophilamodelsystemrevealsuniquepropertiesforf14512anovelpolyaminecontaininganticancerdrugthattargetstopoisomeraseii
AT kasemmanuel integrateddrosophilamodelsystemrevealsuniquepropertiesforf14512anovelpolyaminecontaininganticancerdrugthattargetstopoisomeraseii